Results from the ReOpen1 and ReOpen2 trials, both spanning 24 weeks, revealed that XHANCE significantly improved symptoms, sinus opacification, and quality of life for CRS patients, regardless of ...

Key secondary endpoints included loss of smell score, the Sinonasal Outcome Test (SNOT-22), the Lund–Mackay score assessing sinus opacification, total symptom score, and the rate of nasal polyp ...

The extent of surgery should not be planned solely based on arbitrary criteria regarding minimal level of mucosal thickening, sinus opacification, or outflow obstruction on CT scan.

Data evaluating computed tomography (CT) scans demonstrated numerical improvement in ethmoid sinus opacification in patients who received LYR-210, compared to sham control at week 20 (-2.15; p=0. ...

The exhalation delivery system with fluticasone (EDS-FLU) improved symptoms and sinus opacification in patients with chronic rhinosinusitis without nasal polyps according to phase 3 trial findings ...

Among patients reporting any perceived degree of disease improvement despite treatment, mean changes in in CT scans of sinuses as scored by sinus opacification were at least –2.86, or at least ...

In these trials, XHANCE improved symptoms, sinus opacification, and quality of life in both groups of CRS patients either with or without prior sinus surgery, indicating that previous surgery is ...

Despite improvements in some secondary measures, such as the Sino-Nasal Outcome Test (SNOT-22) score, ethmoid sinus opacification did not significantly improve.

LYR-210 was not associated with a statistically significant improvement in ethmoid sinus opacification compared with sham.

The CT (computed tomography) scan of paranasal sinuses (Figure 1) showed a radio-opaque foreign body (FB) in the left ethmoid sinus with opacification of all sinuses on the left side.

Ethmoid sinus opacification (evaluated by computed tomography (CT) scans), did not achieve statistically significant improvement after treatment with LYR-210 compared to sham control.